Advertisement
China Kangtai CEO Jinjiang Wang said, "We look forward to working withHawk Associate, which has been providing comprehensive strategic IR servicesfor 14 years in their roles as trusted advisors. We believe Hawk Associates isone of the premier investor relations firms that effectively helps companiessuccessfully communicate their stories to the investment community. Thebranding and investor relations expertise that Hawk provides will be essentialin assisting management in showcasing the true value of our company."
Advertisement
Hawk Associates CEO Frank Hawkins said, "As the dominant producer with 60%market share of China's edible cactus production, China Kangtai is a majorbeneficiary of growing Chinese demand for health and wellness products. InChina, cactus products are traditionally used for treatment for health issuessuch as diabetes, adiposity, constipation, cholesterol, high blood pressure,low immunity and skin disorders. This is a unique company in an unsaturatedindustry. With the company's recent acquisition in March, Kangtai is seekingto increase its production capabilities in an effort to enhance its overallgrowth. We are thrilled to be able to help Kangtai tell its story to theinvestment community to strengthen its long-term valuation."
About China Kangtai Cactus Biotech, Inc.
China Kangtai Cactus Biotech Inc. is a leading grower, developer, producerand marketer of cactus-derived products, including nutraceuticals, nutritionalfood and drinks, and animal feed. China Kangtai controls over 387 acres ofplants and maintains an active R&D group that holds 18 product patents and isseeking another 12 in a variety of product categories. China Kangtai'shigh-quality "green" products are sold throughout China in supermarkets, foodstores, hotels and restaurants through a growing distribution network that hascurrently covered 12 provinces and 2 municipalities. For more information,please contact: Chengzhi Wang, General Manager of China Kangtai Cactus Biotech,Inc. Email: [email protected]
For more investor-related questions, contact Susan Zhou, Hawk Associates,at 305-451-1888. To subscribe to future releases via e-mail alert, visithttp://www.hawkassociates.com/about/alert/ .
This news release contains forward-looking statements as defined by thePrivate Securities Litigation Reform Act of 1995. Forward-looking statementsinclude statements concerning plans, objectives, goals, strategies, futureevents or performance, and underlying assumptions and other statements thatare other than statements of historical facts. These statements are subject touncertainties and risks including, but not limited to, product and servicedemand and acceptance, changes in technology, economic conditions, the impactof competition and pricing, government regulation, and other risks containedin reports filed by the company with the Securities and Exchange Commission.All such forward-looking statements, whether written or oral, and whether madeby or on behalf of the company, are expressly qualified by the cautionarystatements and any other cautionary statements which may accompany theforward-looking statements. In addition, the company disclaims any obligationto update any forward-looking statements to reflect events or circumstancesafter the date hereof.
SOURCE China Kangtai Cactus Biotech, Inc.
